You are here: Industry Insights > gilead

News List

Cash-rich but growth-stymied Gilead promotes dealmaker Dickinson to top strategy post fiercepharma
June 06, 2018
After Gilead reported that its revenues plummeted 21% in the first quarter to $5.1 billion, its executives promised 2018 is merely a “trough year”...
Gilead expands operations in Cork, Ireland pharmafile
May 25, 2018
Gilead has unveiled the expansion of its Cork manufacturing site, involved in the creation of its treatments for HIV and hepatitis.
With hepatitis C in freefall, Gilead's bottoming out. The good news? It's bottoming out fiercebiotech
May 03, 2018
Gilead Sciences may have some exciting prospects on the horizon, but for now, its cash-cow hepatitis C business is a big drag. After hepatitis C sales cratered in the first quarter—falling even more than expected...
Gilead, Verily ally to analyze immune cells from inflammatory disease patients fiercebiotech
May 02, 2018
Gilead has teamed up with Verily to analyze the effect its drugs have on the immune cells of patients with inflammatory diseases.
US court upholds verdict voiding MSD's claim to $200m from Gilead in patent dispute pharmafile
April 27, 2018
MSD has taken a legal hit after a US appeals court upheld a ruling that the pharma giant had illicitly obtained patent rights for the treatment of hepatitis C, voiding its claim to an infringement verdict against Gilead to the tune of $200 million.
Astellas sells certain U.S. research facilities to Gilead biospectrumasia
April 23, 2018
The facilities transfer is part of the wind-down process of the Agensys research operations.
Evaluating Risk: Gilead Sciences, Biogen and Celgene biospace
April 08, 2018
When it comes to large-cap biotech companies, Gilead Sciences, Biogen and Celgene are always worth investment consideration, but are not without their risks.
Can Gilead Develop a Cure for HIV? biospace
March 21, 2018
Since its first emergence in the early 1980s, HIV has gone from a terminal and untreatable disease to one that can be managed more like a chronic illness. But so far a “cure” has eluded scientists.
Switching to Gilead's Biktarvy proves non-inferior in HIV patients pharmafile
March 07, 2018
Gilead has unveiled findings from two Phase 3 studies into the efficacy of switching to its three-drug combo Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) from a range of regimens.
Gilead investigational data gives hope for HIV eradication in humans pharmafile
March 06, 2018
Gilead has lifted the curtain on new preclinical data on the efficacy of a combo therapy of GS-9620

Previous page 1 2 3 4 5 6 7 8 9 10 ... 21 22 Next page